This site uses cookies to store information on your computer. I'm fine with this Cookie information

NHSGGC at Leading Edge of Innovative Trials

Wednesday, November 18, 2015

NHS Greater Glasgow and Clyde (NHSGGC) is at the forefront of innovative technology with the potential to save and improve the lives of thousands of people who’ve had a stroke. 

NHSGGC is a leading partner funding Aurum Biosciences to undertake this new ground-breaking technology at the Queen Elizabeth University Hospital (QEUH). 

The Glasgow Oxygen Level Dependent (GOLD) technology uses an injectable agent, perflourocarbon (PFC) oxygen, and MRI scanning. 

With over £3 million invested the clinical trials will allow doctors to detect brain tissue at risk, thus helping doctors to diagnose and improve the care of stroke victims. 

Dr Celestine Santosh, Neuroradiologist at the QEUH, said:  “This is an exciting trial which I am delighted to be part of. 

“This new technology uses an injectable oxygen carrier which, if injected shortly after a stroke is expected to protect brain tissue at risk and reduce the impact of stroke on the patient. 

“This injectable agent when used with MRI scanners will also allow clinicians to detect the areas of the brain under risk, allowing them treat patients who currently are not eligible. 

“This completely innovative technology will revolutionise the way that stroke is managed and will help to increase the number of lives saved and further improve the lives of those who recover from stroke.” 

Aileen MacLennan, Director of Diagnostics, NHSGGC, added:  “Diagnostic Imaging is at the forefront of Imaging techniques and Imaging research. 

“We have recently installed a 256 slice CT scanner and 3T MRI scanners funded by the University of Glasgow which are a welcome addition to our existing 18 CT scanners  and 15 MRI NHS scanners making Diagnioctivc Imaging within NHSGGC the largest single patient Imaging service in Europe

“Diagnostic Imaging Research is integral to medical research and a key component of patient clinical trials, the outcome of the research will potentially impact positively on the clinical pathway and outcomes for our patients.” 

ENDS 

Notes to Editors 

Aurum Biosciences is funded by NHS Greater Glasgow and Clyde, University of Glasgow, the Wellcome Trust, with contributions from angel investment group TRICap, the Scottish Investment Bank, UK and US private investors. 

Scottish Health Innovations Ltd (SHIL), the commercial innovation arm of the NHS in Scotland played a critical role in helping to establish Aurum and bringing the funding package together. 

For further information either telephone 0141 201 4429 or email [email protected]

           

Search by :

Keyword :

Start Date :

End Date :